TITLE

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

AUTHOR(S)
Farfan-Portet, MarĂ­a-Isabel; Gerkens, Sophie; Lepage-Nefkens, Isabelle; Vinck, Irmgard; Hulstaert, Frank
PUB. DATE
April 2014
SOURCE
European Journal of Health Economics;Apr2014, Vol. 15 Issue 3, p223
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article reflects on whether biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures. It is said that a brief reminder of the differences between generics and biosimilars is required before presenting evidence on biosimilar competition. It is also said that biosimilar competition will most probably differ from generic competition.
ACCESSION #
94872176

 

Related Articles

  • Focus on Lowest Net Cost Drug Reduces Costs for Patients, Plan Sponsors. Felthouse, Dana H. // American Health & Drug Benefits;Nov/Dec2008, Vol. 1 Issue 9, p10 

    The article addresses the need for drug benefit plan sponsors and beneficiaries in the U.S. to understand the safety and effectiveness of generic drugs. The growing availability of generic drugs is driving down the rate of growth in prescription drug expenditures. The introduction of incentives...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • A Generic Solution.  // Business NH Magazine;Mar2004, Vol. 21 Issue 3, p7 

    Focuses on New Hampshire-based CIGNA Pharmacy Management's Generic Plus and Generic Solutions generic conversion program. Benefits to members.

  • Report from: Japan. Wan, Jane // Pharmaceutical Technology;May2009, Vol. 33 Issue 5, p18 

    The article focuses on the efforts of the Japanese government in implementing generic drugs and its impact to the healthcare system in Japan. It mentions that generic drug substitution was introduced to the public in April 2006 and cites the cooperation of doctors in rendering prescriptions and...

  • Generic Drugs Face Regulatory and Scientific Challenges. Wechsler, Jill // BioPharm International;Aug2013, Vol. 26 Issue 8, p10 

    The article discusses legislative, regulatory and scientific challenges facing the generic drugs sector. The developments in the sector as the U.S. Food and Drug Administration (FDA) celebrates the one-year anniversary of the Generic Drug User Fee Amendments (GDUFA) of 2012 are discussed. The...

  • Go Go Generics.  // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p24 

    The article discusses developments in the market for generic drugs since the introduction of the Hatch-Waxman Act in the U.S. in 1984. It mentions that generics comprised 70 percent of prescription drugs in the country which are promoted by health plan providers and pharmacy benefit managers...

  • Authorized generics gaining popularity. Johnsen, Michael // Drug Store News;9/26/2005, Vol. 27 Issue 12, p56 

    Reports that branded pharmaceutical companies in the U.S. are turning more and more to authorized generics as part of a viable drug life cycle. Percentage share of branded generics in the pharmaceutical market for the year ended in June 2005; Branded companies still battling generics...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics